{
  "abstract": "I read with great interest the article by Mitsue Saito and colleagues.1 The study reported that cadonilimab combined with chemotherapy achieved remarkably strong antitumor activity (objective response rate (ORR), 81.4% and disease control rate (DCR), 97.7%) in 43 enrolled participants and may represent a promising first-line treatment option for patients with advanced esophageal squamous cell carcinoma (ESCC). Although this single-arm phase II trial met its primary endpoint (ORR), several important issues warrant further clarification.",
  "authors": [
    {
      "affiliations": [
        "Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"
      ],
      "name": "Bi-Cheng Wang"
    }
  ],
  "title": "Cadonilimab (mono anti-PD-1/CTLA-4 therapy) in advanced esophageal squamous cell carcinoma",
  "uid": "2da3b3ad-6933-5fdc-9b88-0606f30a47e1"
}